2001
Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial
Bear H, Roberts J, Cornell D, Tombes M, Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunology, Immunotherapy 2001, 50: 269-274. PMID: 11499810, PMCID: PMC11036846, DOI: 10.1007/s002620100199.Peer-Reviewed Original ResearchConceptsIL-2 infusionAdoptive immunotherapyClinical trialsInterleukin-2Low-dose interleukin-2Tumor-sensitized T cellsPhase I clinical trialLymph node cellsPilot clinical trialLymph node lymphocytesTarget cell numberCell numberNode lymphocytesNode cellsTumor regressionT cellsT lymphocytesUnexpected toxicitiesMurine modelAdditional trialsInfusionPhase ITrialsTechnical modificationsPatient cells
1998
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clinical Cancer Research 1998, 4: 611-8. PMID: 9533528.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBryostatinsCohort StudiesCytotoxicity, ImmunologicDrug Administration ScheduleFemaleHumansImmunophenotypingInfusions, IntravenousInterleukin-2LactonesLymphocyte ActivationLymphocytesLymphomaMacrolidesMaleMetabolic Clearance RateMiddle AgedNeoplasmsPatient SelectionPlatelet AggregationProtein Kinase CConceptsPhase Ib trialIb trialCohort 3Lymphokine-activated killer cell activityBryostatin 1Bryostatin-1 administrationObjective clinical responsesKiller cell activityLiver function testsSubset of patientsBryostatin 1 treatmentSignificant posttreatment increasePKC activitySplit courseClinical responseFirst doseLiver metastasesNonhematological malignanciesRefractory malignanciesFunction testsPatient cohortCohort 1Interleukin-2Immunophenotypic profileTransient elevation
1993
Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2
Huot AE, Moore AL, Roberts JD, Hacker MP. Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2. Immunological Investigations 1993, 22: 319-327. PMID: 7689536, DOI: 10.3109/08820139309063411.Peer-Reviewed Original ResearchConceptsLymphocyte proliferationBAL cellsIL-2Nitric oxideNO synthase inhibitor NG-monomethylSynthase inhibitor NG-monomethylExcess IL-2Bronchoalveolar lavage cellsInhibitor NG-monomethylCytokines IL-2Time of sacrificeIL-2 productionInterleukin-2 productionModulate lymphocyte proliferationSource of NOIL-2-dependent CTLL-2 cellsLavage cellsNG-monomethylCytokine releaseIntratracheal doseCTLL-2 cellsL-arginineLymphocyte growthMarked inhibitionNO inhibits